Literature DB >> 1402661

Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.

M H Malim1, W W Freimuth, J Liu, T J Boyle, H K Lyerly, B R Cullen, G J Nabel.   

Abstract

The human immunodeficiency virus (HIV) Rev protein is essential for viral structural protein expression (Gag, Pol, and Env) and, hence, for viral replication. In transient transfection assays, mutant forms of Rev have been identified that inhibit wild-type Rev activity and therefore suppress viral replication. To determine whether such transdominant Rev proteins could provide long-term protection against HIV infection without affecting T cell function, T leukemia cell lines were stably transduced with a retroviral vector encoding a transdominant mutant of the Rev protein, M10. While all the M10-expressing cell lines remained infectable by HIV-1, these same cells failed to support a productive replication cycle when infected with a cloned isolate of HIV-1. In addition, two out of three M10-expressing CEM clones were also resistant to highly productive infection by a heterogeneous HIV-1 pool. Expression of M10 did not affect induction of HIV transcription mediated by the kappa B regulatory element or Tat. Importantly, constitutive expression of Rev M10 did not alter the secretion of interleukin 2 in response to mitogen stimulation of EL-4 and Jurkat cells. The inhibition of HIV infection in cells stably expressing a transdominant Rev protein, in the absence of any deleterious effect on T cell function, suggests that such a strategy could provide a therapeutic effect in the T lymphocytes of acquired immunodeficiency syndrome patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1402661      PMCID: PMC2119391          DOI: 10.1084/jem.176.4.1197

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids.

Authors:  H S Olsen; A W Cochrane; P J Dillon; C M Nalin; C A Rosen
Journal:  Genes Dev       Date:  1990-08       Impact factor: 11.361

2.  U1 small nuclear RNA plays a direct role in the formation of a rev-regulated human immunodeficiency virus env mRNA that remains unspliced.

Authors:  X B Lu; J Heimer; D Rekosh; M L Hammarskjöld
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Regulation by HIV Rev depends upon recognition of splice sites.

Authors:  D D Chang; P A Sharp
Journal:  Cell       Date:  1989-12-01       Impact factor: 41.582

4.  Expression of human class II major histocompatibility complex antigens using retrovirus vectors.

Authors:  A J Korman; J D Frantz; J L Strominger; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.

Authors:  M H Malim; J Hauber; S Y Le; J V Maizel; B R Cullen
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

6.  Gene therapy. Intracellular immunization.

Authors:  D Baltimore
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

7.  Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector.

Authors:  P A Hantzopoulos; B A Sullenger; G Ungers; E Gilboa
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme.

Authors:  E F Terwilliger; B Godin; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

9.  Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.

Authors:  S Y Kim; R Byrn; J Groopman; D Baltimore
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

10.  Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells.

Authors:  G J Nabel; S A Rice; D M Knipe; D Baltimore
Journal:  Science       Date:  1988-03-11       Impact factor: 47.728

View more
  61 in total

1.  Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73.

Authors:  B E Sawaya; K Khalili; J Gordon; A Srinivasan; M Richardson; J Rappaport; S Amini
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines.

Authors:  N Srinivasakumar; N Chazal; C Helga-Maria; S Prasad; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  cis expression of the F12 human immunodeficiency virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication-defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails.

Authors:  E Olivetta; K Pugliese; R Bona; P D'Aloja; F Ferrantelli; A C Santarcangelo; G Mattia; P Verani; M Federico
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication.

Authors:  Jun Yi; Wei-Dong Gong; Ling Wang; Rui Ling; Jiang-Hao Chen; Jun Yun
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

Review 5.  HIV/AIDS eradication.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Bioorg Med Chem Lett       Date:  2013-05-18       Impact factor: 2.823

6.  A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.

Authors:  M Federico; F Nappi; G Ferrari; C Chelucci; F Mavilio; P Verani
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.

Authors:  G P Kobinger; A Borsetti; Z Nie; J Mercier; N Daniel; H G Göttlinger; A Cohen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle.

Authors:  Sook-Kyung Lee; Janera Harris; Ronald Swanstrom
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

9.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

10.  Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody.

Authors:  L Duan; O Bagasra; M A Laughlin; J W Oakes; R J Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.